Vokanamet

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

canagliflozin, metformin hidroklorid

Available from:

Janssen-Cilag International NV

ATC code:

A10BD16

INN (International Name):

canagliflozin, metformin

Therapeutic group:

Zdravila, ki se uporabljajo pri diabetesu

Therapeutic area:

Diabetes Mellitus, tip 2

Therapeutic indications:

Vokanamet je navedeno pri odraslih, starih 18 let in več, z vrsto 2 sladkorna bolezen kot dodatek k prehrani in vadbi za izboljšanje glycaemic nadzor:pri bolnikih, ki ni ustrezno nadzorovana na njihovo maksimalno dopustne koncentracije metforminom alonein bolnikov na njihovo maksimalno dopustne koncentracije metforminom skupaj z drugimi glukoze znižanje medicini, vključno z insulina, ko te ne zagotavljajo ustrezne glycaemic nadzor. pri bolnikih, ki se že zdravijo z kombinacijo canagliflozin in metforminom kot ločene tabletsFor študijski rezultati glede kombinacija terapij, vplivi na glycaemic nadzor in srčno-žilne dogodke, in populacije, ki je študiral glej poglavji 4. 4, 4. 5 in 5.

Product summary:

Revision: 22

Authorization status:

Pooblaščeni

Authorization date:

2014-04-23

Patient Information leaflet

                                43
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 30

C.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgija
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/14/918/001 (50 mg/850 mg - 20 filmsko obloženih tablet)
EU/1/14/918/002 (50 mg/850 mg - 60 filmsko obloženih tablet)
EU/1/14/918/004 (50 mg/1.000 mg - 20 filmsko obloženih tablet)
EU/1/14/918/005 (50 mg/1.000 mg - 60 filmsko obloženih tablet)
EU/1/14/918/007 (150 mg/850 mg - 20 filmsko obloženih tablet)
EU/1/14/918/008 (150 mg/850 mg - 60 filmsko obloženih tablet)
EU/1/14/918/010 (150 mg/1.000 mg - 20 filmsko obloženih tablet)
EU/1/14/918/011 (150 mg/1.000 mg - 60 filmsko obloženih tablet)
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
vokanamet 50 mg/850 mg
vokanamet 50 mg/1.000 mg
vokanamet 150 mg/850 mg
vokanamet 150 mg/1.000 mg
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
44
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC
SN
NN
45
PODATKI NA PRIMARNI OVOJNINI
NALEPKA NA PLASTENKI
1.
IME ZDRAVILA
Vokanamet 50 mg/850 mg filmsko obložene tablete
Vokanamet 50 mg/1.000 mg filmsko obložene tablete
Vokanamet 150 mg/850 mg filmsko obložene tablete
Vokanamet 150 mg/1.000 mg filmsko obložene tablete
kanagliflozin/metforminijev klorid
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena tableta vsebuje 50 mg kanagliflozina v obliki kanagliflozinijevega
hemihidrata in 850 mg
metforminijevega klorida.
Ena tableta vsebuje 50 mg kanagliflozina v obliki kanagliflozinijevega
hemihidrata in 1.000 mg
metforminijevega klorida.
Ena tableta vsebuje 150 mg kanagliflozina v obliki
kanagliflozinijevega hemihidrata in 850 mg
metforminijevega klorida.
Ena tableta vsebuje 150 mg kanagliflozina v obliki
kanagliflozinijevega hemihi
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Vokanamet 50 mg/850 mg filmsko obložene tablete
Vokanamet 50 mg/1.000 mg filmsko obložene tablete
Vokanamet 150 mg/850 mg filmsko obložene tablete
Vokanamet 150 mg/1.000 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Vokanamet 50 mg/850 mg filmsko obložene tablete
Ena tableta vsebuje 50 mg kanagliflozina v obliki kanagliflozinijevega
hemihidrata in 850 mg
metforminijevega klorida.
Vokanamet 50 mg/1.000 mg filmsko obložene tablete
Ena tableta vsebuje 50 mg kanagliflozina v obliki kanagliflozinijevega
hemihidrata in 1.000 mg
metforminijevega klorida.
Vokanamet 150 mg/850 mg filmsko obložene tablete
Ena tableta vsebuje 150 mg kanagliflozina v obliki
kanagliflozinijevega hemihidrata in 850 mg
metforminijevega klorida.
Vokanamet 150 mg/1.000 mg filmsko obložene tablete
Ena tableta vsebuje 150 mg kanagliflozina v obliki
kanagliflozinijevega hemihidrata in 1.000 mg
metforminijevega klorida.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta
Vokanamet 50 mg/850 mg filmsko obložene tablete
Tableta je roza, ovalna, dolga 20 mm, filmsko obložena z vtisnjeno
oznako "CM" na eni in "358" na
drugi strani.
Vokanamet 50 mg/1.000 mg filmsko obložene tablete
Tableta je bež, ovalna, dolga 21 mm, filmsko obložena z vtisnjeno
oznako "CM" na eni in "551" na
drugi strani.
Vokanamet 150 mg/850 mg filmsko obložene tablete
Tableta je svetlo rumena, ovalna, dolga 21 mm, filmsko obložena z
vtisnjeno oznako "CM" na eni in
"418" na drugi strani.
Vokanamet 150 mg/1.000 mg filmsko obložene tablete
Tableta je vijolična, ovalna, dolga 22 mm, filmsko obložena z
vtisnjeno oznako "CM" na eni in "611"
na drugi strani.
3
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Vokanamet je indicirano pri odraslih s sladkorno boleznijo
tipa 2 kot dodatno zdravljenje ob
ustrezni dieti in telesni dejavnosti:

pri bolnikih, pri katerih glikemija s samostojno uporabo metformina v
največjih odmerkih
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 28-07-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 28-07-2023
Public Assessment Report Public Assessment Report Bulgarian 15-05-2014
Patient Information leaflet Patient Information leaflet Spanish 28-07-2023
Public Assessment Report Public Assessment Report Spanish 15-05-2014
Patient Information leaflet Patient Information leaflet Czech 28-07-2023
Public Assessment Report Public Assessment Report Czech 15-05-2014
Patient Information leaflet Patient Information leaflet Danish 28-07-2023
Public Assessment Report Public Assessment Report Danish 15-05-2014
Patient Information leaflet Patient Information leaflet German 28-07-2023
Public Assessment Report Public Assessment Report German 15-05-2014
Patient Information leaflet Patient Information leaflet Estonian 28-07-2023
Public Assessment Report Public Assessment Report Estonian 15-05-2014
Patient Information leaflet Patient Information leaflet Greek 28-07-2023
Public Assessment Report Public Assessment Report Greek 15-05-2014
Patient Information leaflet Patient Information leaflet English 28-07-2023
Public Assessment Report Public Assessment Report English 15-05-2014
Patient Information leaflet Patient Information leaflet French 28-07-2023
Public Assessment Report Public Assessment Report French 15-05-2014
Patient Information leaflet Patient Information leaflet Italian 28-07-2023
Public Assessment Report Public Assessment Report Italian 15-05-2014
Patient Information leaflet Patient Information leaflet Latvian 28-07-2023
Public Assessment Report Public Assessment Report Latvian 15-05-2014
Patient Information leaflet Patient Information leaflet Lithuanian 28-07-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 28-07-2023
Public Assessment Report Public Assessment Report Lithuanian 15-05-2014
Patient Information leaflet Patient Information leaflet Hungarian 28-07-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 28-07-2023
Public Assessment Report Public Assessment Report Hungarian 15-05-2014
Patient Information leaflet Patient Information leaflet Maltese 28-07-2023
Public Assessment Report Public Assessment Report Maltese 15-05-2014
Patient Information leaflet Patient Information leaflet Dutch 28-07-2023
Public Assessment Report Public Assessment Report Dutch 15-05-2014
Patient Information leaflet Patient Information leaflet Polish 28-07-2023
Public Assessment Report Public Assessment Report Polish 15-05-2014
Patient Information leaflet Patient Information leaflet Portuguese 28-07-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 28-07-2023
Public Assessment Report Public Assessment Report Portuguese 15-05-2014
Patient Information leaflet Patient Information leaflet Romanian 28-07-2023
Public Assessment Report Public Assessment Report Romanian 15-05-2014
Patient Information leaflet Patient Information leaflet Slovak 28-07-2023
Public Assessment Report Public Assessment Report Slovak 15-05-2014
Patient Information leaflet Patient Information leaflet Finnish 28-07-2023
Public Assessment Report Public Assessment Report Finnish 15-05-2014
Patient Information leaflet Patient Information leaflet Swedish 28-07-2023
Public Assessment Report Public Assessment Report Swedish 15-05-2014
Patient Information leaflet Patient Information leaflet Norwegian 28-07-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 28-07-2023
Patient Information leaflet Patient Information leaflet Icelandic 28-07-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 28-07-2023
Patient Information leaflet Patient Information leaflet Croatian 28-07-2023
Public Assessment Report Public Assessment Report Croatian 15-05-2014

Search alerts related to this product

View documents history